266 related articles for article (PubMed ID: 12601084)
1. Common molecular determinants of flecainide and lidocaine block of heart Na+ channels: evidence from experiments with neutral and quaternary flecainide analogues.
Liu H; Atkins J; Kass RS
J Gen Physiol; 2003 Mar; 121(3):199-214. PubMed ID: 12601084
[TBL] [Abstract][Full Text] [Related]
2. Lidocaine alters activation gating of cardiac Na channels.
Hanck DA; Makielski JC; Sheets MF
Pflugers Arch; 2000 Apr; 439(6):814-21. PubMed ID: 10784357
[TBL] [Abstract][Full Text] [Related]
3. Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations.
Liu H; Tateyama M; Clancy CE; Abriel H; Kass RS
J Gen Physiol; 2002 Jul; 120(1):39-51. PubMed ID: 12084774
[TBL] [Abstract][Full Text] [Related]
4. Cardiac-specific external paths for lidocaine, defined by isoform-specific residues, accelerate recovery from use-dependent block.
Lee PJ; Sunami A; Fozzard HA
Circ Res; 2001 Nov; 89(11):1014-21. PubMed ID: 11717158
[TBL] [Abstract][Full Text] [Related]
5. Molecular determinants of state-dependent block of voltage-gated sodium channels by pilsicainide.
Desaphy JF; Dipalma A; Costanza T; Bruno C; Lentini G; Franchini C; George A; Conte Camerino D
Br J Pharmacol; 2010 Jul; 160(6):1521-33. PubMed ID: 20590641
[TBL] [Abstract][Full Text] [Related]
6. Molecular determinants of drug access to the receptor site for antiarrhythmic drugs in the cardiac Na+ channel.
Qu Y; Rogers J; Tanada T; Scheuer T; Catterall WA
Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11839-43. PubMed ID: 8524860
[TBL] [Abstract][Full Text] [Related]
7. Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor.
Bannister ML; Alvarez-Laviada A; Thomas NL; Mason SA; Coleman S; du Plessis CL; Moran AT; Neill-Hall D; Osman H; Bagley MC; MacLeod KT; George CH; Williams AJ
Br J Pharmacol; 2016 Aug; 173(15):2446-59. PubMed ID: 27237957
[TBL] [Abstract][Full Text] [Related]
8. State-dependent block of wild-type and inactivation-deficient Na+ channels by flecainide.
Wang GK; Russell C; Wang SY
J Gen Physiol; 2003 Sep; 122(3):365-74. PubMed ID: 12913091
[TBL] [Abstract][Full Text] [Related]
9. Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels.
Ragsdale DS; McPhee JC; Scheuer T; Catterall WA
Proc Natl Acad Sci U S A; 1996 Aug; 93(17):9270-5. PubMed ID: 8799190
[TBL] [Abstract][Full Text] [Related]
10. Block of wild-type and inactivation-deficient cardiac sodium channels IFM/QQQ stably expressed in mammalian cells.
Grant AO; Chandra R; Keller C; Carboni M; Starmer CF
Biophys J; 2000 Dec; 79(6):3019-35. PubMed ID: 11106609
[TBL] [Abstract][Full Text] [Related]
11. Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers.
Lu HR; Rohrbacher J; Vlaminckx E; Van Ammel K; Yan GX; Gallacher DJ
Br J Pharmacol; 2010 May; 160(1):60-76. PubMed ID: 20331615
[TBL] [Abstract][Full Text] [Related]
12. Blockade of lysophosphatidylcholine-modified cardiac Na channels by a lidocaine derivative QX-222.
Undrovinas AI; Makielski JC
Am J Physiol; 1996 Aug; 271(2 Pt 2):H790-7. PubMed ID: 8770124
[TBL] [Abstract][Full Text] [Related]
13. Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome.
Abriel H; Wehrens XH; Benhorin J; Kerem B; Kass RS
Circulation; 2000 Aug; 102(8):921-5. PubMed ID: 10952963
[TBL] [Abstract][Full Text] [Related]
14. Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide.
Nagatomo T; January CT; Makielski JC
Mol Pharmacol; 2000 Jan; 57(1):101-7. PubMed ID: 10617684
[TBL] [Abstract][Full Text] [Related]
15. Flecainide sensitivity of a Na channel long QT mutation shows an open-channel blocking mechanism for use-dependent block.
Zhu Y; Kyle JW; Lee PJ
Am J Physiol Heart Circ Physiol; 2006 Jul; 291(1):H29-37. PubMed ID: 16501012
[TBL] [Abstract][Full Text] [Related]
16. Outward stabilization of the S4 segments in domains III and IV enhances lidocaine block of sodium channels.
Sheets MF; Hanck DA
J Physiol; 2007 Jul; 582(Pt 1):317-34. PubMed ID: 17510181
[TBL] [Abstract][Full Text] [Related]
17. Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block.
Desaphy JF; De Luca A; Didonna MP; George AL; Camerino Conte D
J Physiol; 2004 Jan; 554(Pt 2):321-34. PubMed ID: 14608015
[TBL] [Abstract][Full Text] [Related]
18. Assessing use-dependent inhibition of the cardiac Na(+/-) current (I(Na)) in the PatchXpress automated patch clamp.
Penniman JR; Kim DC; Salata JJ; Imredy JP
J Pharmacol Toxicol Methods; 2010; 62(2):107-18. PubMed ID: 20601018
[TBL] [Abstract][Full Text] [Related]
19. Unexpected mexiletine responses of a mutant cardiac Na+ channel implicate the selectivity filter as a structural determinant of antiarrhythmic drug access.
Sasaki K; Makita N; Sunami A; Sakurada H; Shirai N; Yokoi H; Kimura A; Tohse N; Hiraoka M; Kitabatake A
Mol Pharmacol; 2004 Aug; 66(2):330-6. PubMed ID: 15266024
[TBL] [Abstract][Full Text] [Related]
20. [New aspects of the molecular effect of anti-arrhythmia agents].
Honerjäger P
Herz; 1990 Apr; 15(2):70-8. PubMed ID: 2160907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
